Newsroom
Welcome to the PWN4PWN Newsroom — your source for the latest updates, announcements, and media coverage about our work and the evolving world of narcolepsy and idiopathic hypersomnia.
Putting the Pieces Together, One Story at a Time
Our work is powered by people — and that includes you. If you’re part of the press, a patient advocacy group, or just curious about what we’re building, this is the space to stay connected.
Be sure to check back regularly for updates and follow us on social media for real-time news from the frontlines of narcolepsy and IH advocacy.
News From around the Community
09/10/2025
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
09/10/2025
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
09/08/2025
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
07/25/2025
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Older News
12/25/24
HCPlive Sleep Medicine Year in Review: 2024
09/25/24
AVADEL Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate)
09/27/24
CENTESSA Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 Agonist, at the 27th Congress of the European Sleep Research Society
09/03/24
PWN4PWN Welcomes Kyle Chastain as New Treasurer on Board of Directors
07/31/24
AVADEL Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
06/03/24
TAKEDA Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
02/21/24
Harmony Biosciences U.S. Food and Drug Administration has granted priority review for Harmony Biosciences’ application for WAKIX® (pitolisant) in pediatric narcolepsy
01/24/24
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing